ESMO–ESGO–ESTRO consensus conference on endometrial cancer: Diagnosis, treatment and follow-up

Nicoletta Colombo(University of Milano-Bicocca), Cristiana Sessa(Institute of Oncology Research), Remi A. Nout(Erasmus MC Cancer Institute), Tjalling Bosse(Leiden University Medical Center), Christian Marth(Nordic Society of Gynecologic Oncology), Antonio González-Martı́n(Spanish Ovarian Cancer Research Group), Carien L. Creutzberg(Leiden University Medical Center), Jonathan A. Ledermann(London Cancer), Mansoor Raza Mirza(C4 Therapeutics (United States)), Denis Querleu(Agostino Gemelli University Polyclinic), Frédéric Amant(Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital)
Radiotherapy and Oncology
December 1, 2015
10.1016/j.radonc.2015.11.013
Cited by 184

Related Papers

Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
|New England Journal of Medicine|2016|2.5k
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma
|International Journal of Gynecological Cancer|2020|1.9k
ESMO-ESGO-ESTRO Consensus Conference on Endometrial Cancer: diagnosis, treatment and follow-up
|Annals of Oncology|2015|1.4k
ESMO–ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
|Annals of Oncology|2019|1.2k
Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2013|1.1k